Literature DB >> 20107031

Anti-endothelial cell antibodies in systemic sclerosis.

C Mihai1, J W C Tervaert.   

Abstract

Anti-endothelial cell antibodies (AECA) are a heterogeneous class of antibodies whose role in the pathogenesis of autoimmune diseases with vascular involvement has been extensively studied. Systemic sclerosis (SSc) is one of the systemic autoimmune diseases in which endothelial dysfunction is well defined and important in the development of the disease. AECA are present in the serum samples of many patients with SSc. Depending on the detection method and on patient selection, 22-86% of patients test positive for AECA. Among the demonstrated clinical associations, lung and peripheral vascular involvement are the most common. In this paper, the methods of detection, various molecular specificities and the possible pathogenic mechanisms of AECA in SSc are reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107031     DOI: 10.1136/ard.2008.102400

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  37 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

2.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy.

Authors:  Takashi Yamashita; Yoshihide Asano; Ryosuke Saigusa; Takashi Taniguchi; Megumi Hirabayashi; Takuya Miyagawa; Kouki Nakamura; Shunsuke Miura; Ayumi Yoshizaki; Maria Trojanowska; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2018-11-30       Impact factor: 8.551

Review 4.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

5.  Identification of Novel Biomarkers for Behcet Disease Diagnosis Using Human Proteome Microarray Approach.

Authors:  Chao-Jun Hu; Jian-Bo Pan; Guang Song; Xiao-Ting Wen; Zi-Yan Wu; Si Chen; Wen-Xiu Mo; Feng-Chun Zhang; Jiang Qian; Heng Zhu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2016-10-24       Impact factor: 5.911

Review 6.  The right ventricle in scleroderma (2013 Grover Conference Series).

Authors:  Paul M Hassoun
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

7.  Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.

Authors:  Chieh-Yu Shen; Ko-Jen Li; Pei-Hsuan Lai; Chia-Li Yu; Song-Chou Hsieh
Journal:  Clin Rheumatol       Date:  2017-09-23       Impact factor: 2.980

8.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

Review 9.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

Review 10.  Molecular and cellular basis of scleroderma.

Authors:  Beate Eckes; Pia Moinzadeh; Gerhard Sengle; Nico Hunzelmann; Thomas Krieg
Journal:  J Mol Med (Berl)       Date:  2014-07-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.